By: FDA

The U.S. Food and Drug Administration approved Ebanga (Ansuvimab-zykl), a human monoclonal antibody, for the treatment for Zaire ebolavirus (Ebolavirus) infection in adults and children. Ebanga blocks binding of the virus to the cell receptor, preventing its entry into the cell.

Read more: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-treatment-ebola-virus